Description

Tesamorelin 10 mg — GHRH Analog for Visceral Fat & Endocrine Research

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog designed to stimulate endogenous growth hormone (GH) secretion via pituitary GHRH receptors. In preclinical and clinical research, Tesamorelin has been studied for its effects on visceral adipose tissue (VAT), body composition, and metabolic/endocrine markers, particularly in settings of altered fat distribution.

What It Is

• Class: GHRH (growth hormone–releasing hormone) analog
• Concept: Mimics native GHRH signaling to increase pulsatile GH release and secondarily influence IGF-1 and downstream metabolic endpoints.
• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

GHRH–Pituitary Axis

• Activates GHRH receptors on pituitary somatotroph cells.
• Engages cAMP/PKA signaling pathways linked to GH synthesis and secretion.
• Supports pulsatile GH release rather than continuous exogenous GH exposure.

Downstream Body-Composition Effects

• Research explores changes in visceral adipose tissue, trunk fat, and overall body-composition indices.
• Model-dependent effects on IGF-1 levels, lipid profiles, and metabolic markers.
• Interest in differentiation between subcutaneous vs. visceral fat responses.
• Investigations into lean mass preservation in research models with altered body composition.

Selected Research Highlights

• Visceral Fat Reduction: Tesamorelin has been investigated for selective reductions in visceral adipose tissue across multiple clinical and preclinical studies, with effects reported to be sustained over treatment periods.
• Endocrine Markers: Research examines changes in IGF-1, growth hormone pulsatility, and related endocrine endpoints.
• Lipid Profile Studies: Investigations into triglycerides, cholesterol fractions, and other metabolic markers in subjects with altered fat distribution.
• HIV-Associated Lipodystrophy Research: Tesamorelin has been characterized extensively in research populations with HIV-related changes in fat distribution.

Chemical & Handling Information

• Type: Synthetic GHRH analog peptide
• Backbone: Modified human GHRH (1–44) sequence with N-terminal trans-3-hexenoyl modification for enzymatic stability (exact sequence per lot specification)
• Appearance: White to off-white lyophilized powder
• Solubility: Reconstitutes readily in bacteriostatic water or sterile saline for laboratory preparation

Specifications

• Peptide: Tesamorelin
• Amount: 10 mg per vial
• Form: Lyophilized powder
• Purity: ≥99% (HPLC); COA per lot available
• Packaging: Sealed glass vials with rubber stopper and aluminum crimp seal, suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place, protected from light.
• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability, in accordance with standard laboratory SOPs.
• After reconstitution, store at 2–8 °C for short-term laboratory use (typically up to 30 days).
• For long-term storage of reconstituted material, aliquot and freeze at −20 °C or below.
• Avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Use Disclaimer

This product is sold strictly for laboratory research use only. Not intended for human or animal consumption. Not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. Customers are solely responsible for the lawful handling, storage, and use of this product in accordance with all applicable laws and regulations.